Phase 1
๐ Investigational Drug / Biologic
NCT06830863
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
๐ Genesis Cancer and Blood Institute โ Hot Springs, Arkansas
View Study & Screener โ